Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

Biotechsamy Jun. 25 at 1:15 AM

$LEGN nothing new, just additional info on underwriters https://www.wsgr.com/en/insights/firm-advises-underwriters-on-legend-biotechs-public-offering.html#:~:text=In%20addition%2C%20Legend%20Biotech%20has%20granted%20the,the%20underwriters'%20option%20to%20purchase%20additional%20ADSs.

0 · Reply

Biotechsamy Jun. 24 at 8:24 PM

$LEGN FWIW

0 · Reply

CloudMatt Jun. 24 at 2:42 PM

$LEGN Probably a good time to buy now. Glad I got the chance to get some more.

0 · Reply

DCZ Jun. 24 at 1:05 PM

$LEGN hopefully once the selling pressure is done with the public offering closing we can start the grind back up to $50+. We have a nice tailwind with the xbi at the moment which should help

0 · Reply

Biotechsamy Jun. 23 at 8:12 PM

$LEGN Hopefully the follow on offering closed today. The today’s closing price matches the offering price. Let’s wait for next catalyst. Hopefully they will share the (good) data publicly first and let the street decide.

0 · Reply

KY3000 Jun. 23 at 5:18 PM

$LEGN @kiwisurfer

1 · Reply

KY3000 Jun. 23 at 1:53 PM

$LEGN this offering looks like something to make some big shareholders happy. 1 ADR =2 shares of the company. Nice payday at 80$

1 · Reply

Biotechsamy Jun. 23 at 11:51 AM

$LEGN Abbvie’s market cap increased immediately after spending $10B to acquire Apogee Therapeutics. “Have to imagine every M&A banker on the planet is watching what happened in the pharma sector yesterday . Acquirer added more market cap than the acquired.”

1 · Reply

KY3000 Jun. 23 at 9:20 AM

$LEGN Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors | AJMC https://www.ajmc.com/view/legend-biotech-s-car-t-cell-therapy-shows-early-promise-in-sclc-other-tumors

0 · Reply

Biotechsamy Jun. 23 at 8:58 AM

$LEGN “China approves the world’s first CAR-T therapy (by CARsgen) for a solid tumor.” Legend has NOT given clinical update on their autologous CAR-T against same target (claudin) for same indication (solid tumor-Gastric cancer) for more than a year. May be Legend is working on making a next version a better version.

0 · Reply

Legend Biotech falls -14.4%

2026-06-18T14:07:36.000Z - 6 days ago

Legend Biotech falls -12.2%

2026-06-18T02:05:06.000Z - 7 days ago

Legend Biotech 7.7M share Spot Secondary priced at $29.35

Jun 17, 2026, 9:21 PM EDT - 7 days ago

Legend Biotech Corporation Announces Pricing of Public Offering

2026-06-17T21:10:10.000Z - 7 days ago

Legend Biotech secondary offering; price range $29.35-$31.35

2026-06-17T20:36:48.000Z - 7 days ago

Legend Biotech announces $225M offering of American Depositary Shares

Jun 17, 2026, 4:29 PM EDT - 7 days ago

Legend Biotech Corporation Announces Proposed Public Offering

2026-06-16T18:45:37.000Z - 8 days ago

Legend Biotech management to meet with Oppenehimer

2026-06-15T12:13:53.000Z - 9 days ago

Legend Biotech announces clinical proof-of-concept data for LB2501

$Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma$

Jun 15, 2026, 8:00 AM EDT - 9 days ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

2026-06-14T20:50:52.000Z - 10 days ago

Legend Biotech announces first clinical proof-of-concept data for LB2501

2026-06-03T11:33:22.000Z - 21 days ago

Legend Biotech price target raised to $49 from $31 at UBS

2026-06-03T10:16:18.000Z - 21 days ago

Legend Biotech price target raised to $65 from $50 at H.C. Wainwright

2026-06-02T17:21:37.000Z - 22 days ago

This Is Why Legend Biotech Stock (LEGN) Was Up Today

2026-06-02T16:18:47.000Z - 22 days ago

Legend Biotech rises 29.5%

2026-06-02T14:06:38.000Z - 22 days ago

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

Jun 2, 2026, 9:31 AM EDT - 22 days ago

Legend's experimental cell therapy shows promise in blood cancer patients

Jun 2, 2026, 9:30 AM EDT - 22 days ago

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

2026-06-01T16:05:07.000Z - 23 days ago

Legend Biotech presents first-in-human LB2102 results in solid tumors

Jun 1, 2026, 10:00 AM EDT - 23 days ago

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

May 31, 2026, 7:00 PM EDT - 24 days ago

Legend Biotech Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2026

May 21, 2026, 5:00 PM EDT - 4 weeks ago

Legend Biotech Announces Presentations at ASCO 2026

2026-05-13T16:55:07.000Z - 6 weeks ago

Legend Biotech price target lowered to $48 from $49 at Morgan Stanley

2026-05-13T15:57:12.000Z - 6 weeks ago

Legend Biotech price target raised to $29 from $21 at TD Cowen

2026-05-13T15:00:09.000Z - 6 weeks ago

Legend Biotech price target raised to $64 from $62 at RBC Capital

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Legend Biotech Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Legend Biotech Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Legend Biotech Slides: Q1 2026

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 4, 2026, 8:00 AM EDT - 7 weeks ago

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Slides: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 24, 2026, 8:00 AM EST - 4 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

Jan 14, 2026, 12:00 PM EST - 5 months ago

Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 5 months ago

Legend Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 3:31 PM EST - 7 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

Dec 6, 2025, 2:00 PM EST - 7 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Dec 3, 2025, 7:00 AM EST - 7 months ago

Legend Biotech Slides: Corporate presentation

Nov 13, 2025, 12:08 PM EST - 7 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Legend Biotech Slides: Q3 2025

Nov 3, 2025, 11:05 AM EST - 8 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 9 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Sep 9, 2025, 4:05 PM EDT - 10 months ago

Legend Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Legend Biotech Slides: Corporate Presentation

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Legend Biotech Slides: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jul 1, 2025, 10:00 AM EDT - 1 year ago

Legend Biotech Slides: Corporate Presentation

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 1 year ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 1 year ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Annual report: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Slides: FY 2025

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 8, 2024, 11:00 PM EST - 1 year ago

Legend Biotech Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Slides: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 4, 2024, 2:35 PM EDT - 1 year ago

Legend Biotech Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings Call Transcript: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings release: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Slides: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jun 6, 2024, 10:30 AM EDT - 2 years ago

Legend Biotech Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 4:00 PM EDT - 2 years ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

Biotechsamy Jun. 25 at 1:15 AM

0 · Reply

Biotechsamy Jun. 24 at 8:24 PM

$LEGN FWIW

0 · Reply

CloudMatt Jun. 24 at 2:42 PM

$LEGN Probably a good time to buy now. Glad I got the chance to get some more.

0 · Reply

DCZ Jun. 24 at 1:05 PM

$LEGN hopefully once the selling pressure is done with the public offering closing we can start the grind back up to $50+. We have a nice tailwind with the xbi at the moment which should help

0 · Reply

Biotechsamy Jun. 23 at 8:12 PM

0 · Reply

KY3000 Jun. 23 at 5:18 PM

$LEGN @kiwisurfer

1 · Reply

KY3000 Jun. 23 at 1:53 PM

$LEGN this offering looks like something to make some big shareholders happy. 1 ADR =2 shares of the company. Nice payday at 80$

1 · Reply

Biotechsamy Jun. 23 at 11:51 AM

1 · Reply

KY3000 Jun. 23 at 9:20 AM

$LEGN Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors | AJMC https://www.ajmc.com/view/legend-biotech-s-car-t-cell-therapy-shows-early-promise-in-sclc-other-tumors

0 · Reply

Biotechsamy Jun. 23 at 8:58 AM

0 · Reply

Biotechsamy Jun. 23 at 2:49 AM

$LEGN The follow-on offering is expected to be closed on Tuesday June 23, 2026.

0 · Reply

guggles Jun. 23 at 12:54 AM

$LEGN deal by August?

1 · Reply

DiamondHandsBTW Jun. 22 at 3:19 PM

$LEGN abbvie is up on the apogee deal 6% shows that Wall Street rewards good acquisitions. I hope JnJ sees this too

1 · Reply

BioTechHealthX Jun. 21 at 3:28 PM

$LEGN Legend Biotech Corporation (LEGN) has a 78.73% upside estimate, a $6.24 billion market cap, and fresh early-stage cancer therapy data. Here’s why this high-science biotech stock is getting serious attention. https://biotechhealthx.com/biotech-news/is-legend-biotech-legn-a-smart-buy-for-investors-betting-on-cancer-cell-therapy/

0 · Reply

kiwiSurfer Jun. 21 at 3:19 PM

$LEGN $JNJ will not get outbid fot $LEGN but won’t put it past $NVS ot $LLY getting into a bidding war for $LEGN just to make it more expensive for their competitor $JNJ…

1 · Reply

BioTechHealthX Jun. 21 at 10:06 AM

$COGT $INSM $LEGN $PCVX $SMMT These 5 healthcare stocks are drawing attention from Wall Street analysts because of strong stock upside, clinical trial updates, market expansion, biotech innovation, and major healthcare growth catalysts. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-that-could-turn-a-1000-investment-into-something-bigger/

0 · Reply

KY3000 Jun. 21 at 9:59 AM

$LEGN rumors apogee getting bought by abbvie 11$ bill for phase 2.

0 · Reply

k3vl4r Jun. 20 at 8:01 PM

watching $LEGN right now - eps estimates just jumped hard, up nearly 300 basis points for next year. worth digging into what's driving that. https://app.k3vl4r.com/?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=LEGN #stocks

0 · Reply

Biotechsamy Jun. 20 at 12:10 AM

$LEGN JnJ is building in-house team/talent on ex Vivo and in Vivo CAR-T discovery. In big pharma, these teams are typically like care-takers of adopted babies.

1 · Reply

Biotechsamy Jun. 19 at 11:02 PM

$LEGN A tale of two deals. A case in point: Apogee Therapeutics in May 2026 vs June 2026

1 · Reply

SQUEAKSBANDIT Jun. 19 at 4:00 AM

$LEGN not cambridge not la jolla not sanfran but the biotwch hotbed of Somerset nj how did they end up in somerset nj?

0 · Reply

guggles Jun. 19 at 1:14 AM

$LEGN buyout , let's go

0 · Reply

Market Cap	5.44B
Revenue (ttm)	1.03B
Net Income (ttm)	-296.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	620.67
Profit Margin	-28.85%
Debt to Equity Ratio	0.27

Volume	2,077,900
Avg Vol	2,993,670
Day's Range	N/A - N/A
Shares Out	185.74M
Stochastic %K	20%
Beta	0.35
Analysts	Strong Sell
Price Target	$58.53